Hiding in Plain Sight: How Cancer Evades the Immune System

Slides:

Advertisements

Similar presentations

The principle of immunotherapy using dendritic cell vaccine: (1) monocytes are isolated from the peripheral blood and (2,3) manipulated in experimental.

Advertisements

Activation of T Lymphocytes

Critical Reviews in Oncology / Hematology

Nivolumab Drugbank ID : DB09035 Molecular Weight (Daltons) :

Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Atezolizumab Drugbank ID : DB11595.

Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll Cancer Cell

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Tumor Immunity: Exploring the Role of a Checkpoint

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

The Immune System. The Immune System Adaptive Immune Response.

by Jennifer Couzin-Frankel

T-Cell Exhaustion: Can We Overcome It in Cancer?

Small but Mighty: Selected Commensal Bacterial Species Determine the Effectiveness of Anti-cancer Immunotherapies Jose R. Conejo-Garcia, Melanie R. Rutkowski

Discussion Outline Cells of the Immune System.

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Merkel Cell Carcinoma: What Do Clinicians Need to Know?

The yin and yang of evasion and immune activation in HCC

Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4.

Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers Ivana Catacchio, Anna Scattone, Nicola.

The Tumor Microenvironment

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 1 Four nodes to target when inducing anti-tumour immunity

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review Am J Nephrol 2017;45: DOI: / Fig. 1. CTLA-4 and PD-1.

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Tumor Evolution: A Problem of Histocompatibility

Nat. Rev. Urol. doi: /nrurol

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Activity Goals. Activity Goals Program Overview.

Improving Outcomes in Psoriatic Arthritis

Tumor Immunity ——卓越一班二组——. Tumor Immunity ——卓越一班二组——

The yin and yang of evasion and immune activation in HCC

Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

The Changing Field of Melanoma: Ipilimumab.

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Mechanism of CTLA-4-induced immunosuppression.

Nat. Rev. Endocrinol. doi: /nrendo

Schematic representation of mechanisms leading to the synergy of anti-CD137 and anti–PD-1 immunostimulatory mAbs. Schematic representation of mechanisms.

Challenges and Opportunities

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

Yibin Kang, Klaus Pantel Cancer Cell

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

Figure 1 Mechanisms of action of immunotherapy modalities

Deciphering and Reversing Tumor Immune Suppression

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

Cancer Evolution during Immunotherapy

Michele De Palma, Rakesh K. Jain Immunity

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Mesenchymal Stromal Cells: New Directions

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

The Nurse View.

by Jennifer Couzin-Frankel

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Illustration of cancer cells and tumor microenvironment–deregulated miRNA target networks leading to tumor growth and progression. Illustration of cancer.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific activation of a naïve or memory T cell.

Immune escape mechanisms in cancer.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Anti–PD-1/PD-L1–mediated acquired resistance is dependent on CD38-generated adenosine in the tumor microenvironment. Anti–PD-1/PD-L1–mediated acquired.

Presentation transcript:

Hiding in Plain Sight: How Cancer Evades the Immune System

Cancer Immunoediting Elimination➛ Equilibrium➛ Escape

Proinflammatory Reaction Within the Tumor Microenvironment

Tumor Cell-Mediated Immune Escape Aberrant Signal 1, 2, or 3 in the Tumor Microenvironment

Tumor Cell-Mediated Immune Escape Providing an Aberrant Signal 2

Control of the T Cell

Activating and Inhibitory Receptors

CTLA4 in Immune Cell Deactivation

Anti-CTLA4 Antibody in Immune Cell Activation

Ipilimumab-Derived Rashes

The Immune Synapse

PD-1/PD-L1 in the Immune Response

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)